Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Phase 2

Recruiting

• Conditions: Obesity
• Interventions: Drug: Petrelintide; Drug: Placebo

• Registration Number: NCT06662539
• Lead Sponsor: Zealand Pharma

Brief Summary

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

Detailed Description

Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management.

This is a randomized, double-blind, placebo-controlled, parallel-group, multinational, multicenter, dose-finding, Phase 2 clinical trial. The trial will compare 5 doses of once-weekly (OW) subcutaneously administered petrelintide with placebo.

This study consists of 3 periods:

1. A screening period of 2-3 weeks

2. A treatment period of 42 weeks

3. A safety follow-up period of 9 weeks.

Study Timeline

• Study First Submitted: 2024-10-25
• Study First Submitted QC: 2024-10-25
• Study First Posted: 2024-10-29
• Status Verified: 2024-12
• Study Start: 2024-12-09
• Last Update Submitted: 2024-12-18
• Last Update Posted: 2024-12-24
• Primary Completion: 2025-11-07
• Study Completion: 2026-04-17

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

• Male or female participants having body mass index (BMI) ≥30.0 kg/m2 or BMI ≥27.0 kg/m2 with the presence of at least one of the following comorbidities: hypertension or dyslipidemia (treated or untreated).

• A female participant is eligible to participate if she is:

  • A woman of nonchildbearing potential. OR
  • A woman of childbearing potential (WOCBP) who is not pregnant, does not intend to be pregnant, not lactating and is willing to use highly effective contraceptive methods (as required by local regulation or practice) throughout the trial and for 10 weeks after the last injection of the investigational medicinal product (IMP).

• Ability to comply with the protocol requirements including self-administration of IMP with vial and syringe.

Read More

Exclusion Criteria

• Glycated hemoglobin (HbA1c) ≥48 mmol/mol (6.5%), as measured at screening.
• History of type 1 or type 2 diabetes mellitus.
• Treatment with glucose lowering agent(s) within 90 days prior to screening.
• A self-reported change in body weight >5% within 90 days prior to screening.
• Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 6 months prior to screening.
• Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g. sleeve, banding or similar) that have been removed more than 6 months prior to screening, are allowed.
• Uncontrolled thyroid disease defined as thyroid stimulating hormone >4.20 mIU/L or <0.27 mIU/L as measured by the central laboratory at screening.
• Lifetime history of a suicidal attempt.
• History of major depressive disorder or other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder).
• Estimated glomerular filtration rate value <60.0 mL/min/1.73m2, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) Creatinine Equation17, measured at screening.
• Impaired liver function, defined as alanine aminotransferase and/or aspartate aminotransferase ≥2.0 times or bilirubin >1.5 times upper normal limit, measured at screening.
• Presence or history of acute or chronic pancreatitis.
• Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronic treatment that affects gastrointestinal (GI) motility.
• Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation.
• Presence or history of clinically significant arrhythmias or clinically significant conduction disorders.
• Known or suspected hypersensitivity to amylin analogs or related products.
• History of malignant neoplasms (except for basal or squamous cell skin cancer) within 5 years prior to screening.
• Known or suspected abuse of alcohol or recreational drugs.
• Participant previously treated with petrelintide or any other amylin analog.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Petrelintide Dose 1	Petrelintide	Participants will self-inject petrelintide dose 1 subcutaneously once a week.
Petrelintide Dose 2	Petrelintide	Participants will self-inject petrelintide dose 2 subcutaneously once a week.
Petrelintide Dose 3	Petrelintide	Participants will self-inject petrelintide dose 3 subcutaneously once a week.
Petrelintide Dose 4	Petrelintide	Participants will self-inject petrelintide dose 4 subcutaneously once a week.
Petrelintide Dose 5	Petrelintide	Participants will self-inject petrelintide dose 5 subcutaneously once a week.
Placebo	Placebo	Participants will self-inject matching placebo to petrelintide subcutaneously once a week.

Primary Outcome Measures

Name	Time	Method
Percent change from baseline in body weight to Week 28	From Baseline (Day 1) to Week 28	To compare the dose-response of increasing doses of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity after 28 weeks of exposure.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants achieving ≥5% Body Weight Loss at Weeks 28 and 42	From Baseline (Day 1) to Weeks 28 and 42	To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Percentage of Participants achieving ≥10% Body Weight Loss at Weeks 28 and 42	From Baseline (Day 1) to Weeks 28 and 42	To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in body weight to Weeks 28 and 42	From Baseline (Day 1) to Weeks 28 and 42	To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in waist circumference to Weeks 28 and 42	From Baseline (Day 1) to Weeks 28 and 42	To compare the efficacy of petrelintide versus placebo on waist circumference, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Percent change from baseline in body weight to Week 42	From Baseline (Day 1) to Week 42	To compare the efficacy of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in hemoglobin A1c (HbA1c) to Week 42	From Baseline (Day 1) to Week 42	To compare the efficacy of petrelintide versus placebo on HbA1c, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in fasting glucose to Week 42	From Baseline (Day 1) to Week 42	To compare the efficacy of petrelintide versus placebo on fasting glucose, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in high-sensitivity C-reactive protein (hsCRP) to Week 42	From Baseline (Day 1) to Week 42	To compare the efficacy of petrelintide versus placebo on hsCRP, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Change from baseline in fasting lipids to Week 42	From Baseline (Day 1) to Week 42	To compare the efficacy of petrelintide versus placebo on fasting lipids, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Number of treatment emergent adverse events (TEAEs)	From Baseline (Day 1) to Week 51	To compare the safety and tolerability of petrelintide versus placebo when added as an adjunct to a reduced-calorie diet and increased physical activity.
Occurrences of anti-drug antibodies (ADAs) to petrelintide	From Baseline (Day 1) to Week 51	To compare the safety and tolerability of petrelintide versus placebo when added as an adjunct to a reduced-calorie diet and increased physical activity.

Trial Locations

Locations (33)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Noble Clinical Research; 🇺🇸 Tucson, Arizona, United States

Excel Medical Clinical Trials, LLC; 🇺🇸 Boca Raton, Florida, United States

Innovative Research of West Florida, Inc.; 🇺🇸 Clearwater, Florida, United States

Century Research LLC; 🇺🇸 Miami, Florida, United States

Clinical Research Center of Florida; 🇺🇸 Pompano Beach, Florida, United States

Palm Beach Research Center; 🇺🇸 West Palm Beach, Florida, United States

Great Lakes Clinical Trials LLC dba Flourish Research; 🇺🇸 Chicago, Illinois, United States

AMR Wichita East; 🇺🇸 Wichita, Kansas, United States

Alliance For Multispecialty Research, LLC; 🇺🇸 Lexington, Kentucky, United States

Mercury Street Medical Group, PLLC; 🇺🇸 Butte, Montana, United States

CHEAR Center LLC; 🇺🇸 Bronx, New York, United States

Javara Inc; 🇺🇸 Charlotte, North Carolina, United States

PharmQuest Life Sciences, LLC; 🇺🇸 Greensboro, North Carolina, United States

Lucas Research, Inc.; 🇺🇸 New Bern, North Carolina, United States

AMR Norman; 🇺🇸 Norman, Oklahoma, United States

Altoona Center for Clinical Research - Research; 🇺🇸 Duncansville, Pennsylvania, United States

Alliance for Multispecialty Research; 🇺🇸 Knoxville, Tennessee, United States

Clinical Trials of Texas, LLC., dba Flourish Research; 🇺🇸 San Antonio, Texas, United States

Manaasas Clinical Research Center; 🇺🇸 Manassas, Virginia, United States

Krakowskie Centrum MedyczneSp.z o.o; 🇵🇱 Krakow, Malopolskie, Poland

ETG Siedlce; 🇵🇱 Siedlce, Mazowieckie, Poland

FutureMeds Warszawa Centrum; 🇵🇱 Warszawa, Mazowieckie, Poland

Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji; 🇵🇱 Warszawa, Mazowieckie, Poland

ETG Warszawa; 🇵🇱 Warszawa, Mazowieckie, Poland

FutureMeds Targowek; 🇵🇱 Warszawa, Mazowieckie, Poland

Futuremeds Olsztyn; 🇵🇱 Olsztyn, Warminsko-mazurskie, Poland

Top Diabet; 🇷🇴 Craiova, Dolj, Romania

Institutul National de Endocrinologie C I Parhon; 🇷🇴 Bucuresti, Romania

Institutul Clinic Fundeni; 🇷🇴 Bucuresti, Romania

Fundatia Dr Victor Babes; 🇷🇴 Bucuresti, Romania

Institutul De Pneumoftiziologie Marius Nasta; 🇷🇴 Bucuresti, Romania

Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta; 🇷🇴 Constanta, Romania